The Companion Diagnostics Development Services Market is projected to grow at an annualized rate of ~5% By Roots Analysis
Roots Analysis has done a detailed report on CompanionDiagnostics Development ServicesMarket, 2020-2030 covering key aspects of theindustry and identifying future growth opportunities
To order this 320+page report, which features 120+ figures and 115+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
Key Market Insights
§ Over 180 companiesfrom different regions across the globe presently claim to provide services forthe development of companion diagnostic tests
§ Currently, a variety of services are available across theentire diagnostics development supply chain, including assays based on a widerange of analytical techniques, especially in the developed geographies
§ Numerous pharmaceutical playersare actively seeking to enter into partnership with companion diagnosticsservice providers, in order to leverage the latter’s expertise in this field
§ The rise in interest in this fieldis reflected in the number of partnerships established in the recent past,involving both international and indigenous stakeholders, and focused on avariety of end objectives
§ In order to achieve an edge overthe contemporary competition, companies engaged in this domain are increasinglyfocusing on the integration of advanced service offerings in their respectiveportfolios
§ The value chain involves drug and diagnostics developers, serviceproviders, along with other important stakeholders, each having a discrete setof priorities and requirements
§ Given the growing demand forprecision medicine, the companion diagnostics services market is expected towitness a double digit growth; the opportunity is likely to be distributedacross different regions and techniques
§ In the long-term, growth in the market is anticipated to be driven bythe clinical studies based on novel tumor markers, which have been identifiedas promising biological targets for development of companion diagnostics
For more information, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. Evolutionof Personalized Medicine
3.3. Overviewof Companion Diagnostics
3.3.1. Developmentof Companion Diagnostics
3.3.2. AnalyticalTechniques Used in Companion Diagnostic Tests
3.3.2.1. Immunohistochemistry
3.3.2.2. Insitu Hybridization
3.3.2.3. PolymeraseChain Reaction
3.3.2.4. DNASequencing / Next Generation Sequencing
3.3.3. Advantagesof Companion Diagnostics
3.4. Applicationsof Companion Diagnostics across Different Therapeutic Areas
3.4.1. Oncology
3.4.2. InfectiousDiseases
3.4.3. NeurologicalDisorders
3.5. RegulatoryReview and Approval Process for Companion Diagnostics
3.6. ExistingChallenges
3.7. FutureRoadmap
4. MARKETLANDSCAPE
4.1. ChapterOverview
4.2. CompanionDiagnostics Service Providers: Overall Market Landscape
4.2.1 Analysisby Type of Service Offered
4.2.2. Analysisby Type of Analytical Technique
4.2.3. Analysisby Regulatory Accreditation / Certification
4.3. CompanionDiagnostics Service Providers: Developer Landscape
4.3.1 Analysisby Year of Establishment
4.3.2 Analysisby Company Size
4.3.3 Analysisby Geographical Location
4.3.4 GridRepresentation: Analysis by Type of Service Offered, Company Size, andGeographical Location
4.3.5 WorldMap Representation: Analysis by Geography
5. COMPANYPROFILES
5.1. ChapterOverview
5.2. KeyPlayers in North America
5.2.1. Asuragen
5.2.1.1. RecentDevelopments and Future Outlook
5.2.2. Covance
5.2.2.1. RecentDevelopments and Future Outlook
5.2.3. Geneuity
5.2.3.1. RecentDevelopments and Future Outlook
5.2.4. MDBiosciences
5.2.4.1. RecentDevelopments and Future Outlook
5.2.5. ResearchDx
5.2.5.1. RecentDevelopments and Future Outlook
5.3. Playersin Europe
5.3.1. AlmacDiagnostic Services
5.3.1.1. RecentDevelopments and Future Outlook
5.3.2. LeicaBiosystems
5.3.2.1. RecentDevelopments and Future Outlook
5.3.3. R-Biopharm
5.3.3.1. RecentDevelopments and Future Outlook
5.3.4. TepnelPharma Services
5.3.4.1. RecentDevelopments and Future Outlook
5.4. KeyPlayers in Asia-Pacific
5.4.1. BARD1Life Sciences
5.4.1.1. RecentDevelopments and Future Outlook
5.4.2. BioMarCareTechnologies
5.4.2.1. RecentDevelopments and Future Outlook
5.4.3. Gencurix
5.4.3.1. RecentDevelopments and Future Outlook
5.4.4. Macrogen
5.4.4.1. RecentDevelopments and Future Outlook
6. PARTNERSHIPSAND COLLABORATIONS
6.1 ChapterOverview
6.2 PartnershipModels
6.3 Listof Partnerships and Collaborations
6.3.1 Analysisby Year of Partnership
6.3.2 Analysisby Type of Partnership
6.3.3 Analysisby Type of Analytical Technique
6.3.4 Analysisby Type of Therapeutic Area
6.3.5 Analysisby Year of Partnership and Type of Partner
6.3.6 Analysisby Type of Partnership and Type of Partner
6.3.7 MostActive Players: Analysis by Number of Partnerships
6.3.8 PopularAnalytical Techniques: Analysis by Number of Partnerships
6.3.9 RegionalAnalysis
6.3.10 Intercontinentaland Intracontinental Agreements
7. LIKELYPARTNER ANALYSIS
7.1. ChapterOverview
7.2. Scopeand Methodology
7.3. ScoringCriteria and Key Assumptions
7.4. LikelyPartners for Companion Diagnostics Service Providers: Alzheimer’s Disease
7.4.1. CompaniesWorking on the Amyloid Beta Biomarker
7.4.1.1. WorldMap Representation: Amyloid Beta Biomarker Focused Clinical Trials
7.4.2. CompaniesWorking on the Tau Biomarker
7.4.2.1. WorldMap Representation: Tau Biomarker Focused Clinical Trials
7.5. LikelyPartners for Companion Diagnostics Service Providers: Breast Cancer
7.5.1. CompaniesWorking on the BRCA Biomarker
7.5.1.1. WorldMap Representation: BRCA Biomarker Focused Clinical Trials
7.5.2. CompaniesWorking on the HER Biomarker
7.5.2.1. WorldMap Representation: HER Biomarker Focused Clinical Trials
7.5.3. CompaniesWorking on the HR Biomarker
7.5.3.1. WorldMap Representation: HR Biomarker Focused Clinical Trials
7.5.4. CompaniesWorking on the PD-L1 Biomarker
7.5.4.1. WorldMap Representation: PD-L1 Biomarker Focused Clinical Trials
7.6. LikelyPartners for Companion Diagnostics Service Providers: Colorectal Cancer
7.6.1. CompaniesWorking on the BRAF Biomarker
7.6.1.1. WorldMap Representation: BRAF Biomarker Focused Clinical Trials
7.6.2. CompaniesWorking on the EGFR Biomarker
7.6.2.1. WorldMap Representation: EGFR Biomarker Focused Clinical Trials
7.6.3. CompaniesWorking on the KRAS Biomarker
7.6.3.1. WorldMap Representation: KRAS Biomarker Focused Clinical Trials
7.6.4. CompaniesWorking on the MSI Biomarker
7.6.4.1. WorldMap Representation: MSI Biomarker Focused Clinical Trials
7.6.5. CompaniesWorking on the NRAS Biomarker
7.6.5.1. WorldMap Representation: NRAS Biomarker Focused Clinical Trials
7.7. LikelyPartners for Companion Diagnostic Service Providers: HIV
7.7.1. CompaniesWorking on the CCR5 Biomarker
7.7.1.1. WorldMap Representation: CCR5 Biomarker Focused Clinical Trials
7.8. LikelyPartners for Companion Diagnostics Service Providers: Lung Cancer
7.8.1. CompaniesWorking on the ALK Biomarker
7.8.1.1. WorldMap Representation: ALK Biomarker Focused Clinical Trials
7.8.2. CompaniesWorking on the EGFR Biomarker
7.8.2.1. WorldMap Representation: EGFR Biomarker Focused Clinical Trials
7.8.3. CompaniesWorking on the PD-L1 Biomarker
7.8.3.1. WorldMap Representation: PD-L1 Biomarker Focused Clinical Trials
7.8.4. CompaniesWorking on the ROS Biomarker
7.8.4.1. WorldMap Representation: ROS Biomarker Focused Clinical Trials
7.9. LikelyPartners for Companion Diagnostics Service Providers: NASH / NAFLD
7.9.1. CompaniesWorking on the AST Biomarker
7.9.1.1. WorldMap Representation: AST Biomarker Focused Clinical Trials
7.10. LikelyPartners for Companion Diagnostics Service Providers: Ovarian Cancer
7.10.1. CompaniesWorking on the BRCA Biomarker
7.10.1.1. World Map Representation: BRCABiomarker Focused Clinical Trials
7.10.2. CompaniesWorking on the CA-125 Biomarker
7.10.2.1. World Map Representation: CA-125Biomarker Focused Clinical Trials
7.11. LikelyPartners for Companion Diagnostics Service Providers: Prostate Cancer
7.11.1. CompaniesWorking on the PTEN Biomarker
7.11.1.1. World Map Representation: PTENBiomarker Focused Clinical Trials
8. COMPANYCOMPETITIVENESS ANALYSIS
8.1 ChapterOverview
8.2 Methodology
8.3 Assumptionsand Key Parameters
8.4 CompanyCompetitiveness Analysis
8.4.1 CompanionDiagnostics Service Providers based in North America
8.4.2 CompanionDiagnostics Service Providers based in Europe
8.4.3 CompanionDiagnostics Service Providers based in Asia Pacific / RoW
9. STAKEHOLDERNEEDS ANALYSIS
9.1. ChapterOverview
9.2. CompanionDiagnostics: Needs of Different Stakeholders
9.3. Comparisonof Needs of Various Stakeholders
9.3.1. Needs of Drug Developers
9.3.2. Needs of Companion Diagnostics Developers
9.3.3. Needs of Regulatory Authorities
9.3.4. Needs of Testing Laboratories
9.3.5. Needs of Payers / Insurance Providers
9.3.6. Needs of Physicians
9.3.7. Needs of Patients
10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. Companion Diagnostics Value Chain: Cost Distribution
10.2.1. Research and Product Development
10.2.2. Manufacturingand Assembly
10.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks
10.2.4. Payer Negotiation and KOL Engagement
10.2.5. Marketing and Sales
10.3. Companion Diagnostics Development Operations: Key Cost Contributors
10.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors
11. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE
11.1. Chapter Overview
11.2. Methodology
11.3. Clinical Trial Analysis
11.3.1. List of Likely Drug Candidates for IVD Developers
11.4. Cumulative Distribution of Biomarker Focused Trials by Registration Year,2016-2019
11.4.1. Analysis of Trials for Most Popular Biomarkers
11.4.2. Analysis of Trials for Moderately Popular Biomarkers
11.4.3. Analysis of Trials for Less Popular / Preliminary Stage Biomarkers
11.4.4. Other Emerging Biomarkers: Word Cloud
11.4.5. Cumulative Distribution of Trials of the Most Popular Biomarkers byRegistration Year
11.4.6. Cumulative Distribution of Trials of the Moderately Popular Biomarkers byRegistration Year
11.4.7. CumulativeDistribution of Trials of the Less Popular Biomarkers by Registration Year
11.5. Analysisof Biomarker Focused Trials for Most Popular Indications
11.5.1. Analysisof Trials for Moderately Popular Indications
11.5.2. Analysisof Trials for Less Popular and Other Indications
11.5.3. OtherEmerging Indications: Word Cloud
11.5.4. CumulativeDistribution of Trials of the Most Popular Indications by Registration Year
11.5.5. CumulativeDistribution of Trials of the Moderately Popular Indications by RegistrationYear
11.5.6. CumulativeDistribution of Trials of the Less Popular / Preliminary Stage Indications byRegistration Year
11.6. Analysis of Biomarker Focused Trials by Phase of Development
11.6.1. Analysisof Trials of the Most Popular Biomarkers
11.6.2. Analysisof Trials of the Moderately Popular Biomarkers
11.6.3. Analysis of Trials of the Less Popular and Other Biomarkers
11.6.4. Analysis of Trials of the Most Popular Indications
11.6.5. Analysis of Trials of the Moderately Popular Indications
11.6.6. Analysis of Trials of the Less Popular and Other Indications
11.7. Analysis of Biomarker Focused Trials by Sponsor
11.7.1. Analysis of Trials of the Most Popular Biomarkers
11.7.2. Analysis of Trials of the Moderately Popular Biomarkers
11.7.3. Analysis of Trials of the Most Popular Indications
11.7.4. Analysis of Trials of the Moderately Popular Indications
11.8. Analysis of Biomarker Focused Trials by Recruitment Status
11.9. Analysis of Biomarker Focused Trials by Therapy Design
11.10. Analysis of Biomarker Focused Trials by Geography
11.10.1. Analysis of Trials by Phase ofDevelopment and Recruitment Status
11.11. ClinicalTrials Summary: Analysis of Biomarker Focused Trials by Most PopularIndications
11.12. ClinicalTrials Summary: Analysis of Biomarker Focused Trials by Moderately PopularIndications
11.13. ClinicalTrials Summary: Analysis of Biomarker Focused Trials by Preliminary StageIndications
12. MARKETFORECAST AND OPPORTUNITY ANALYSIS
12.1 ChapterOverview
12.2. KeyAssumptions and Forecast Methodology
12.3. GlobalCompanion Diagnostics Services Market, 2020-2030
12.3.1. GlobalCompanion Diagnostics Services Market: Distribution by Type of Service Offered,2020 2030
12.3.2. GlobalCompanion Diagnostics Services Market: Distribution by Type of AnalyticalTechnique, 2020-2030
12.3.3. GlobalCompanion Diagnostics Services Market: Distribution by Region, 2020-2030
12.4. CompanionDiagnostics Services Market in North America, 2020-2030
12.4.1. CompanionDiagnostics Services Market in the North America: Distribution by Type ofService Offered, 2020-2030
12.4.2. CompanionDiagnostics Services Market in the North America: Distribution by Type ofAnalytical Technique, 2020-2030
12.5. CompanionDiagnostics Services Market in Europe, 2020-2030
12.5.1. CompanionDiagnostics Services Market in Europe: Distribution by Type of Service Offered,2020-2030
12.5.2. CompanionDiagnostics Services Market in Europe: Distribution by Type of AnalyticalTechnique, 2020-2030
12.6. CompanionDiagnostics Services Market in Asia Pacific and Rest of the World, 2020-2030
12.6.1. CompanionDiagnostics Services Market in Asia Pacific and Rest of the World: Distributionby Type of Service Offered, 2020-2030
12.6.2. CompanionDiagnostics Services Market in Asia Pacific and Rest of the World: Distributionby Type of Analytical Technique, 2020-2030
13. EXECUTIVEINSIGHTS
13.1. ChapterOverview
13.2. TymoraAnalytical Operations
13.2.1. CompanySnapshot
13.2.2. AntonIliuk (President, Chief Technology Officer), Tymora Analytical Operations
13.3. Novodiax
13.3.1. CompanySnapshot
13.3.2. PaulKortschak (Senior Vice President, Novodiax)
13.4. OWLMetabolomics
13.4.1. CompanySnapshot
13.4.2. PabloOrtiz (Chief Executive Officer, OWL Metabolomics)
13.5. NeoGenomicsLaboratories
13.5.1. CompanySnapshot
13.5.2. LawrenceM. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)
14. CONCLUDINGREMARKS
15. APPENDIX1: TABULATED DATA
16. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
